High-dose and low-dose varenicline for smoking cessation in adolescents: a randomised, placebo-controlled trial
High-dose and low-dose varenicline for smoking cessation in adolescents: a randomised, placebo-controlled trial
复制标题
DOI：
10.1016/s2352-4642(20)30243-1
复制
发表时间：
2020-11-01
影响因子：
36.4
通讯作者：
McRae, Thomas D.
中科院分区：
文献类型：
--
作者：
Gray, Kevin M.;Rubinstein, Mark L.;McRae, Thomas D.
虽然吸烟通常始于青少年，但对这一人群进行成功的药物戒烟干预的证据很少。在成年吸烟者中，伐尼克兰是最有效的单一药物治疗。本研究的目的是评估伐尼克兰戒烟的疗效和耐受性在adolescents.Methods我们做了一个随机，安慰剂对照试验，青少年吸烟者年龄在12-19岁谁正在寻求治疗戒烟在57个门诊中心（在美国，俄罗斯，韩国，台湾，加拿大和格鲁吉亚）。参与者被随机分配（1：1：1）接受12周的高剂量伐尼克兰（1 mg，每日两次; 0.5 mg，每日两次，如果体重
Background Although cigarette smoking typically begins in adolescence, evidence for successful pharmacological smoking cessation interventions for this population is scarce. In adult smokers, varenicline is the most effective single pharmacotherapy. The aim of this study was to assess the efficacy and tolerability of varenicline for smoking cessation in adolescents.Methods We did a randomised, placebo-controlled trial with adolescent smokers aged 12-19 years who were seeking treatment to quit at 57 outpatient centres (in the USA, Russia, South Korea, Taiwan, Canada, and Georgia). Participants were randomly assigned (1:1:1) to receive 12 weeks of high-dose varenicline (1 mg twice daily; 0.5 mg twice daily if bodyweight